Overview
- Scientists at McMaster University and SickKids report in Neuron that glioblastoma reprograms nearby oligodendrocytes into a reactive state that secretes CCL5 to activate tumor CCR5.
- Disrupting the CCL5–CCR5 communication in lab systems slowed tumor growth and impaired migration, identifying a druggable signaling pathway.
- Maraviroc, an FDA‑approved CCR5 antagonist for HIV, blocked this axis in preclinical models and prolonged survival in mice, according to the latest coverage.
- The oligodendrocyte-driven program was most enriched in recurrent, treatment‑refractory glioblastoma, underscoring its relevance to advanced disease.
- Researchers are initiating translation through CLIA-certified organoid screening with SAGE Medic and exploring off‑label or compassionate paths, while noting human efficacy remains unproven and will require clinical trials.